Jean-Philippe Herbeuval, DR1 CNRS Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) CNRS UMR8601, Université de Paris Novel pathway to control interferons and inflammation
Jean-Philippe Herbeuval, DR1 CNRSChemistry & Biology, Modeling & Immunology for Therapy (CBMIT)
CNRS UMR8601, Université de Paris
Novel pathway to control interferons and inflammation
ISG: up to 300 genes!
ü Type I IFN are powerful molecules: induce activation of 300-600 genes (called ISG)ü IFNAR are expressed by virtually all the human cells
Interferon-Inflammation: friends or foes?
Immune Surveillance
Viral infection
Bacterial infection
Type I IFN: the good, the bad, and the ugly
Tumor
Chronic viral and bacterial infections
Depression
Autoimmune diseases
Interferono-pathies
SLE
ü Immune cells discovered in 1997, role during innate and adaptive immunity
ü Professional of IFNa production (up to 1000x than other cell type)
ü Powerful but very rare cells: less than 0,5% of PBMC
ü Express innate immune sensors of the Toll-like receptors family (TLR-7 and -9)
ü Express high levels of IRF-7 (regulating IFN genes) and the chemokine receptor CXCR4
ü pDC represent promising cellular target for interferonopathies (SLE, sclerodermia..)
The IFN producers: the plasmacytoid DCs
Sascha Rodes and Nikaïa Smith, Ulm University-CBMIT
Interferons and interferon producing cells
NCI, NIH USA (2001-2006)
pDC
IFN-aTRAIL
(Killer pDC)
This is the first demonstration that natural molecules could block pDCs
TLR7/9
Natural amines block IFN in pDC
Gene Shearer Lab’s, Experimental Immunology Branch, NCI, NIH
R848
RNA/DNA
Virus
HistamineDopamineSerotonin
• Herbeuval et al, Blood 2005• Herbeuval et al, Blood 2005• Herbeuval et al, PNAS 2005• Herbeuval et al, PNAS 2006• Hardy et al, PNAS 2007 • Herbeuval et al, Clin Immu, 2007• Herbeuval et al, AIDS 2009
GlucocorticoidsAnti-BDCA2Antii-TLR7
PGE2
Modulation of interferon production
CNRS, Necker Hospital (2006-2012)
Clobenpropit (CB)
§ Naturel Ligand of HR (GPCR)§ Very unstable (Histaminase)§ Endogenous monoamine § Km (H1R et H2R) = 1000nM§ Km (H3R et H4R) = 5-10 nM
Histamine
§ Pharmacologic analogue§ Very stable§ Agoniste H4R – Km = 1nM§ Antagoniste H3R – IC50 = 10nM
ü Histamine overproduction in atopic children increases viral infection
Modulation of pDC viral activation by histamineEffect of Histamine/CB on pDC
CNRS UMR8147, Hôpital Necker, Michel DY
Flu
Flu+ H
A
Flu+ C
B
50
100
150
200
0
IFN
-apr
oduc
tion
(ng/
mL)
-EL
ISA
Mock
******
**
ü IFN-α production by HIV-stimulated pDC
Non Stimulated 5 10 20 40
BDC
A-4
Flu + CB (µM)
BDC
A-4
BDC
A-4
BDC
A-4
BDC
A-4
BDC
A-4
Flu
IFNa
Histamine
Clobenpropit (CB)
Flu
IFN-IELISAFACS
pDC
Or
Effect of Histamine and CB on pDC activation
pDC
Influenza A virusX31strain (H3N2)
- IFNa, IFNb in BAL- Cytokines - High activation of pDC,
Effect of Histamine/CB in vivo
X31 very pathogenic Flu:
IFN-a IFN-b
S129S8 12 week mice
CB or Histamine450µg/30µL/mouse18h before infection
Influenza A virusX31 (H3N2)
Broncho-alveolar Wash 3 days post-infection
Elisa : IFNa, IFNb
A. Wack (F. Crick Institute)
Effect of Histamine/CB in vivo
Flu Flu Flu Flu Smith et al Nat Comm 2017
Identification of the receptor controlling interferon production
CBMIT, Faculté des Saints-Pères(since 2012)
Fundamental research:Production and regulation of IFN-I
Translational research:Evaluation of therapeutic molecules
Cellular model: innate immunepDC, Monocytes
Integrated model:Human tonsils
In silico modeling
Organic chemistry
Molecular/cellular screening Selection of best molecules
IFN screeningPatients
Clinical network
In silico dockingFunctional screening
Organic chemistryOptimization
In vitro Ex vivo In vivo
Auto-immune pathologies
Interferonopathies
Patients
Auto-immunityInterferonopathies
Viral infection
Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT)Understanding the regulation of type I interferons and inflammation
The chemokine receptor CXCR4 hypothesis
CBMIT, CNRS UMR8601, Université de Paris
HypothesisAmine’s activity is due to:
Their receptor(HR,SR..)
Bind to Toll-like R A common receptor
No No
Could CXCR4 be the common receptor?
ü Amino compounds bind to CXCR4 expressed by neurons
ü CXCR4 is highly expressed by human pDC
ü CXCR4 is a member of the GPCR family (as amine natural receptors)
Nicolas PietrancostaCR1, CNRS
Nikaïa SmithPhD-Posdoc
The chemokine receptor CXCR4: pleiotropic activity
Cell migration HIV coreceptor Tumor migration
Expressed by Hematopoietic Immune cells
NeuronsTumor cells
Chimiotaxism
GPCR family member 7 transmembrane
Natural ligand: CXCL12
Could CXCR4 be the common receptor?
Physiological Pathological
Extracellular domain
0
20
40
60
80
100
120
140
160
Rel
ativ
e m
RN
Aex
pres
sion
leve
ls
siCTR - - + -- ++siCXCR4 - + - ++ --
- + -++ - +-
IFNα Histamine CB Spermine
/
Mock
Silencing of CXCR4 in primary cells
0
20
40
60
80
100
120
140
160
Rel
ativ
e m
RN
Aex
pres
sion
leve
ls
siCTR - - + -- ++siCXCR4 - + - ++ --
- + -++ - +-
IFNα Histamine CB Spermine
Flu
/
Mock
CXCR4
siCTL / siCXCR4
Primary human pDC
CXCR4 siRNAHistamine or CB
+Flu
Flu
§ Synthetic ligand of CXCR4 § Very stable§ Developed by Novartis§ IC50 CXCR4 = 5-10 nM§ EC50 antagonist: 10 nM
IT1t
§ Other name Plerixafor§ Stable/clinically used§ IC50 CXCR4 = 5-10 nM§ EC50 antagonist: 10 nM
AMD3100Plerixafor
CB / IT1t
Structural similarties
CXCR4 specific ligands effect on type I IFN
CXCL12
§ Natural Ligand§ Protein§ Metastasis migration
CB is not a CXCR4 specific ligand, so what about CXCR4 ligands?
Inhibition of IFNa production by CXCR4 ligands
Immunomodulation of IT1t versus AMD3100
Purified pDC
R848
NS 0 0.5 1 5 10 50 µM AMD20
SSC
-A
IFN!
81.6 81.9 82.4 84.3 84.1 82.1 81.51.29
NS 0 0.5 1 5 10 20 500
50
100
150
IFNα
pro
duct
ion
(% o
f R84
8 st
imul
ated
pDC
)
R848 + Compound (µM)
**,xx
**** *,xxxx
***,xx
SSC
-A
R848
NS 0 0.5 1 5 10 50 µM IT1t2081.6 78.8 76.7 49.2 20 3.27 0.921.29
IFN!
Targeting CXCR4 ex vivo with IT1t:SLE model
• Systemic lupus erythematous (SLE) is defined by a complex clinical syndrome (e.g., arthritis,skin rashes, serositis, glomerulonephritis, nervous system involvement) and the production ofantinuclear antibodies (ANAs).
• Some individuals develop a type of skin disease, called cutaneous lupus erythematosus.
Systemic lupus erythematous: symptoms
Kaul et al., (2016) Nat Rev Diseases Primer
pDC & IFN: central players in lupus pathology
Role of IFN-I in systemic lupus erythematous (SLE)
Rodero et al., (2017) J Exp Med
Detecting the Undetectable: Ultrasensitive SiMoA Immunoassay. Digital IFN-a ELISA Complex interferonopathies
v Increased serum levels of IFN-α observed in many SLE patients correlate with both disease activity and key diseasemarkers
Guiducci et al. Nature 2010
v Inhibition of IFN-α/β induced TRAIL expression may reduce symptoms in SLE by stopping pathogenesis of autoantibodyproduction and autoimmune tissue injury
Zahn et al. British j. derm 2011
v Over-production of Type I interferon (IFN-I) is strongly associated with SLE and is involved in disease pathogenesis.Rodero et al. JEM 2017
Lupus is an interferonopathy
Brigitte Badder-MeunierPierre Quartier
HCP9P9 + IT1t
Gated on CD3+ cells
pSTAT1
1
2
3
4
pSTA
T1 (M
FI x
103 )
HD NS IT1t
**
Gated on CD3+ cells
pSTAT3
HCP9P9 + IT1t
2
4
6
8
pSTA
T3 (M
FI x
102 )
HD NS IT1t
**
Mathieu Rodero
+/- IT1t
overnightØ STAT activationØ IFNa productionØ Simoa
PBMC
SpI JuvenilLupus Patients
Ø pSTAT1 (= IFN-I, II)
Ø pSTAT3 (= IL-6)
0.1
1
10
100P6
P4
P5
P3IFNα(
fg/m
l)
IT1t - +
Ø Simoa: IFNa
Ex vivo effect of IT1ton SLE patient
Simoa
HDsP7P8P9
JSLEP4P5 JSLE
HDsP7
P9JSLEP8
P3
P6
Darragh Duffy
Lupus patients
+ R848+/- IT1t
overnightØ IFNa production
Anne-Sophie Korganow
PBMC
0.1
1
10
100
1000
10000
IFNα
(fg/
ml)
Unst 0 5 20R848 + IT1t (µM)
HC3HC4HC5HC6
P3P4P5P6
SLE
*****
ns
SSC
-A
BDCA-4
SSC
-A
IFNa
NS R848 R848 + IT1tHC2
0
1
10
20
1
1
P2
0.34
0.29
Ø Ultrasensitive digital IFNa ELISA (Simoa) Ø Intracellular staining of IFN-a
Ex vivo effect of IT1ton SLE patient
N. Bekadour N. Smith
Targeting CXCR4 with IT1t in vivo:Pristane-induced lupus in mice
10 Male DBA1/J
Pristane (IP) daily+/- Prednisolone+/- IT1t 3 doses
Cytokine in serumAnti-DNA antibodies
at Week 4,8,10
Pristane-induced SLE in mouse model
10 weeks
IT1t
Extracellular
Intracellular
CXCR4
CXCR4
Binding pocket
SLE mice model set upPristane SLE mouse model
0
20
40
60
IL-1β
(pg/
mL)
Week 4 Week 10
******
***
0
10
20
30
40
IL-1
7 (pg
/mL)
Week 4 Week 10
********
*******
0
2
4
6
8
101520
TRAI
L (p
g/m
L)
Week 10
****
*
• SLE is characterized by over-production of cytokines: IL-1b, IL-6, IL-17 and TRAIL• IL-17 Accurate Biomarkers for Systemic Lupus Erythematosus Disease Activity
IL-1b IL-17
TRAIL
0.0
0.5
1.0
1.5
2.0
dsDN
A (1
/50, O
.D.)
VehiclePrednisoloneIT1t - 3mpkIT1t - 10mpkIT1t - 30mpk
Week 4 Week 8 Week 10
* **
*****
****
IT1t effect on cytokine production in SLE in mice
• Systemic lupus erythematous (SLE) is defined by a complex clinical syndromeand the production of antinuclear antibodies (ANAs).
0.0
0.5
1.0
1.5
2.0
anti-
dsDN
A (1
/50,
O.D
.) VehiclePrednisoloneIT1t - 3mpkIT1t - 10mpkIT1t - 30mpk
Week 4 Week 8 Week 10
* **
*****
****
Vehic
lePr
edni
solo
ne3m
pk10
mpk
30m
pk
0
2
4
6
8
Mice
(num
ber)
GPT+GPT-
IT1t
0.0
0.5
1.0
1.5
2.0
dsD
NA
(1/5
0, O
.D.)
VehiclePrednisoloneIT1t - 3mpkIT1t - 10mpkIT1t - 30mpk
Week 4 Week 8 Week 10
* **
*****
****
IT1t effect on anti-dsDNA production SLE mice
Smith et al, 2019
Auto-immune diseases
Biased agonistAntagonist
Anti-tumoral
Inhibition cellular migration Inhibition of immune cells
The CXCR4 drug target
Novel activity
The chemokine receptor CXCR4 (GPCR)
Well-known activity
Cell migration Immune modulation
IFN-driven auto-immune diseases Inflammation-driven auto-immune diseases
Developpment of new anti-inflammatory drugs :Creation of Ermium therapeutics
Pascal NeuvilleCEO-Founder
Thierry LaugelPresident
Hadrien BouchezAssocitae
Nathalie LennePorfolio Director
Joel CrouzetCEO
JP HerbeuvalScientific Founder
Drug design and optimizationHeat/leads development
Preclinical studiesClinical studies
Simon HayekResearcher
§ COLLABORATIONS
§ GRANTS
§ TV (2) § RADIO (1) § PRESS (12)
§ MULTIMEDIA
§ COLLABORATIONS
§ EXPERTISE
§ PUBLICATIONS
§ COVER
Total : 86(Nat Com, Science Adv, Immunity, Plos patho..)
Interface Immunology VirologyNeurology Oncology Chemistry
§ VALORIZATION
6 patents (SATT)4 maturation contracts (SATT)Creation of SantImmune (POV-JPH)
§ START-UP
Ermium Therapeutics